WEBSTER, Texas, April 28, 2011 /PRNewswire/ — IDEV
Technologies, Inc. (IDEV) today announced the firm has received
approval from the Therapeutic Goods Administration (TGA),
Australia’s regulatory agency for medical drugs and devices, for
the SUPERA VERITAS® stent system for use in biliary and
peripheral procedures.
“We are pleased to receive the TGA approval, and look forward to
launching SUPERA VERITAS in the Australian market later this year,”
said Christopher Owens, President and CEO of IDEV. “Australia
represents a leading market in the Asia-Pacific region, and we have
established a wholly owned subsidiary, IDEV Medical Technologies
PTY LTD, in Sydney to support the product registration and
introduction of this unique next generation technology. This
is the first in a series of steps to extend our global footprint as
well as our growth strategy in the Asia-Pacific region.”
Australia represents an established growing peripheral vascular
stent market, with an experienced base of endovascular
physicians.
The SUPERA stent has been recognized as a different class of
stent, based on proprietary technology and mechanical properties
that result in unmatched radial strength and flexibility. It
provides a new treatment option for patients with biliary
strictures or peripheral arterial disease (PAD).
About IDEV Technologies, IncorporatedIDEV Technologies,
Incorporated (IDEV) is an innovator and developer of next
generation medical devices for use in interventional radiology,
vascular surgery and cardiology. IDEV’s worldwide
headquarters is located in Webster, Texas and its European
headquarters is located in Beuningen, The Netherlands. For
more information please visit www.idevmd.com.
The SUPERA stent is currently indicated in the U.S. for the
palliative treatment of biliary strictures produced by malignant
neoplasms and in Europe, Canada and Australia for the
‘/>”/>
SOURCE